Our Investments

SELECT INVESTMENTS

AveXis is a Dallas-based company developing gene therapy for spinal muscular atrophy, an often progressive and disabling muscle wasting disease.

Visit Website

LaJolla Pharmaceutical is a California biotech focused on endogenous peptides and therapies for rare diseases.

Visit Website

ReGenX is the most broadly licensed AAV capsid technology platform in gene therapy. ReGenX’s own pipeline is focused on metabolic, CNS, and retinal diseases.

Visit Website

Immunocore is a London-based company with an immuno-oncology platform technology called ImmTACs. ImmTACs enable the potent targeting of intracellular cancer antigens with controlled pharmacology.

Visit Website

Solid Biosciences is dedicated to developing therapies for Duchenne Muscular Dystrophy, a disease characterized by progressive muscular weakness in boys.

Visit Website

Armo BioSciences is an immuno-oncology company with a pipeline of novel interleukins for cancer.

Visit Website

Odonate Therapeutics is developing a novel oral taxane for breast cancer.

Visit Website

Orchard Therapeutics is a biotechnology company incorporated in September 2015 and dedicated to bringing transformative gene therapies to patients with serious and life-threatening orphan diseases.

Visit Website

Rocket Pharma brings hope and relief to patients with undertreated rare diseases through the development and commercialization of curative first-in-class gene-modified cell therapies.

Visit Website
Attune is developing small molecules for hereditary angioedema.

Visit Website
Establishment Labs is developing safer next-generation cosmetic implants.

Visit Website
Dermtech has developed a non-invasive adhesive patch for the diagnosis of metastatic melanoma.

Visit Website
Beta Bionics is the developer of the iLet®, a revolutionary bionic pancreas driven by machine-learning artificial intelligence to autonomously control blood sugar.

Visit Website
Milestone is a late-stage biopharmaceutical company developing a drug intended to provide outpatient treatment of paroxysmal supraventricular tachycardia (PSVT).

Visit Website
Stoke is developing antisense oligos that target RNA splicing to increase gene expression for the treatment of severe genetic diseases, including Dravet Syndrome.

Visit Website

LET’S TALK

We believe biotech will be a key value creator over the next decade.

Contact us to learn more about RTW’s expertise, insight and experience in identifying and working with companies focused in areas of breakthrough innovation.

  • This field is for validation purposes and should be left unchanged.